000			02047 a2200577 4500
005			20250516153830.0
264		0	_c20140320
008			201403s 0 0 eng d
022			_a1552-4604
024	7		_a10.1002/jcph.116 _2doi
040			_aNLM _beng _cNLM
100	1		_aHan, Tae H
245	0	0	_aCYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. _h[electronic resource]
260			_bJournal of clinical pharmacology _cAug 2013
300			_a866-77 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aBrentuximab Vedotin
650	0	4	_aCross-Over Studies
650	0	4	_aCytochrome P-450 CYP3A _xmetabolism
650	0	4	_aCytochrome P-450 CYP3A Inhibitors
650	0	4	_aDrug Interactions
650	0	4	_aFeces _xchemistry
650	0	4	_aFemale
650	0	4	_aHematologic Neoplasms _xmetabolism
650	0	4	_aHumans
650	0	4	_aImmunoconjugates _xadministration & dosage
650	0	4	_aKetoconazole _xadministration & dosage
650	0	4	_aKi-1 Antigen _ximmunology
650	0	4	_aMale
650	0	4	_aMidazolam _xadministration & dosage
650	0	4	_aMiddle Aged
650	0	4	_aOligopeptides _xmetabolism
650	0	4	_aRifampin _xadministration & dosage
650	0	4	_aYoung Adult
700	1		_aGopal, Ajay K
700	1		_aRamchandren, Radhakrishnan
700	1		_aGoy, Andre
700	1		_aChen, Robert
700	1		_aMatous, Jeffrey V
700	1		_aCooper, Maureen
700	1		_aGrove, Laurie E
700	1		_aAlley, Stephen C
700	1		_aLynch, Carmel M
700	1		_aO'Connor, Owen A
773	0		_tJournal of clinical pharmacology _gvol. 53 _gno. 8 _gp. 866-77
856	4	0	_uhttps://doi.org/10.1002/jcph.116 _zAvailable from publisher's website
999			_c22824428 _d22824428